Cerus (CERS) Projected to Post Quarterly Earnings on Tuesday

Cerus (NASDAQ:CERS) is anticipated to issue its quarterly earnings data after the market closes on Tuesday, March 4th. Analysts expect the company to announce earnings of ($0.01) per share and revenue of $52.95 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Cerus (NASDAQ:CERS) last posted its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, meeting analysts’ consensus estimates of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The company had revenue of $50.81 million during the quarter, compared to analyst estimates of $50.81 million. On average, analysts expect Cerus to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cerus Stock Performance

Shares of CERS opened at $1.64 on Tuesday. Cerus has a one year low of $1.38 and a one year high of $2.59. The company has a 50-day moving average of $1.74 and a two-hundred day moving average of $1.83. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. The stock has a market cap of $304.56 million, a price-to-earnings ratio of -14.91 and a beta of 1.29.

Insiders Place Their Bets

In other Cerus news, Director Eric Bjerkholt sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $1.78, for a total value of $35,600.00. Following the transaction, the director now owns 162,133 shares in the company, valued at approximately $288,596.74. This represents a 10.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.40% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reiterated an “overweight” rating and set a $4.00 price objective on shares of Cerus in a research report on Friday.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.